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Fructose-1,6-bisphosphatase was purified to 
homogeneous state from chicken livers. The functional 
consequences of treating the enzyme with oxidized 
glutathione (GSSG), diethylpyrocarbonate, and 
butanedione were investigated. Activation of the enzyme 
with GSSG, as previously reported from this laboratory, 
was found to be accompanied by alteration of other 
properties, such as reduced sensitivity to fructose 2,6- 
P2 inhibition and loss of activation by K
+. Treatment 
with butanedione leads to desensitization of the enzyme 
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to AMP inhibiton, indicating the presence of arginyl 
residue(s) at the AMP allosteric site. Modification 
with diethylpyrocarbonate results in rapid and almost 
total loss of the catalytic activity, suggesting the 
presence of essential histidine residue at the catalytic 
site. 
Fructose 1,6-bisphosphatase was bound to cysteamine 
-Sepharose by thiol/disulfide exchange with cystamine- 
Sepharose. The immobilized enzyme retained about 80% of 
the specific activity of the free enzyme. The activity 
of the immobilized enzyme could further be enhanced by 
iodoacetamide and cystamine. The optimum pH remained 
essentially unchanged but the pH activity curve became 
much broader. The bound enzyme could be released from 
cysteamine-Sepharose by reduction with dithiothreitol. 
The immobilized enzyme lost about 50% of its activity 
after storage for 3 weeks in 0.5 M NaCl at 4°C. Albumin 
significantly enhanced the stability. The immobilized 
enzyme is more effective than the free form in selective 
hydrolysis of fructose 1,6-bisphosphate in the process 
of fructose 2,6-bisphosphate synthesis. The enzyme was 
also bound to pyridoxal-P-Sepharose through formation of 
Schiff base linkage using the epsilon amino group of 
lysyl residue(s) at the AMP allosteric site. Stable and 
highly active immobilized enzyme was obtained by 
reduction of the Schiff base with NaBH4. 
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CHAPTER I 
REVIEW OF THE LITERATURE 
General Characteristics of FBPase 
Fructose-1,6-bisphosphatase (FBPase)(EC 3.1.3.11), the 
enzyme that catalyzes the hydrolysis of D-fructose-1,6- 
bisphosphate to fructose-6-P and Pi, was first discovered in 
rabbit liver by Gomori in 1943 (Gomori, 1943). This enzyme 
has since then been shown to play a key role in 
gluconeogenesis [for review see (Pontremoli and Horecker, 
1971)] . FBPase is necessary for the formation of glucose 
from fructose, lactate, glycerol, and gluconeogenic amino 
acids (Pontremoli and Grazi, 1968). A defect in this enzyme 
system results in impairment in the gluconeogenic process. 
It has been reported that bacterial mutants lacking FBPase 
were unable to grow on compounds such as glycerol, acetate, 
or succinate as carbon sources (Franenkel and Horecker, 
1965). In humans, the metabolic disorder known as 
"infantile lactic acidosis" has been found to be associated 
with hepatic FBPase deficiency (Baker and Winegrad, 1970; 
Pagliara et al., 1971 and 1972; Baerlocher et al., 1971). 
During the past three decades, FBPases from a wide 
variety of sources have been extensively studied. Some of 
the common properties as well as important studies or 




(a) The native "neutral pH optimum" FBPases isolated 
from different sources are tetramers composed of 
identical subunits of molecular weights ranging 
from about 36,000 to 40,000 (Benkovic and DeMaine, 
1982; Rittenhouse et al., 1983; Marcus et al., 
1982; Han and Johnson, 1982). 
(b) In 1982, Marcus et al. reported the complete amino 
acid sequence of the 335 residues of the pig 
kidney FBPase subunit. In the following year, 
Fisher et al. (1983) reported the complete amino 
acid sequence of sheep liver FBPase. The 
sequences of these two FBPases are quite similar 
with full identity from residue 102 to 139. 
(c) FBPases from all known sources require a divalent 
cation (Mg2+ or Mn2+) for activity (see Pontremoli 
and Horecker, 1971 for review). 
(d) FBPases from most sources are activated by K+ or 
NH4+ (Hubert et al., 1970) and inhibited by Zn2+ 
(Nimmo and Tipton, 1975; Tejwani et al., 1976; Han 
et al., 1978a; Han et al., 1980), AMP (Pontremoli 
and Horecker, 1971; Taketa and Pogell, 1963), 
fructose-2,6-P2 (Hers and van Schaftingen, 1982), 
and high concentration of substrate (Pontremoli 
and Horecker, 1971; Mendicino and Vasarhely, 1963; 
Singh et al., 1980). 
(e) Singh et al. (1980) have recently proposed that 
the mechanism of activation of FBPase by 
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monovalent cations (K+ and NH4+) may be due to the 
reversal of inhibition by excess substrate. 
(f) The inhibition of this enzyme by AMP is allosteric 
in nature (Taketa and Pogell, 1963). This 
inhibition can be totally or nearly totally 
abolished by treatment with butanedione (Marcus, 
1976; Riordan et al., 1977), N-acetylimidazole 
(Pontremoli et al., 1966), pyridoxal-P (Marcus and 
Hubert, 1968; Krulwich et al., 1969; Colombo et 
al., 1972; Han et al., 1983), and acetylsalicylate 
(Han et al., 1978b). It has been suggested that 
arginyl, tyrosyl, and lysyl residues are all 
present at the AMP allosteric site. Han et al. 
(1991) have recently found that acetylsalicylate 
and pyridoxal-P alter the AMP allosteric property 
of turkey liver FBPase by modifying the same lysyl 
residues at the AMP site. 
(g) Most researchers believe that fructose-2,6-P2 
inhibits FBPase by binding to the active site 
resulting in competitive inhibition (Pontremoli et 
al., 1982; Gottschalk et al., 1982; McGrane et 
al., 1983), but Meek and Nimmo (1983) have 
recently proposed that fructose-2,6-P2 may inhibit 
the enzyme by interacting at both the active site 
and an allosteric site which is distinct from the 
AMP site. 
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(h) The inhibitory effects of AMP and fructose-2,6-P2 
are synergistic (Van Schaftingen and Hers, 1981; 
Pilkis et al., 1981). Han et al. (1983) have 
found that these two compounds can synergistically 
protect chicken liver FBPase against inactivation 
by trypsin. 
(i) McGrane et al. (1983) have suggested that the 
binding of fructose-2,6-P2 to FBPase may bring 
about a conformational change which facilitates 
AMP binding. The effect of fructose-2,6-P2 on the 
chemical modification of the AMP site has been 
studied. Pilkis et al. (1981) have reported that 
fructose-2,6-P2 can almost completely protect rat 
liver FBPase against desensitization to AMP 
inhibition by N-acetylimidazole, while Pontremoli 
et al. (1982) and Gottschalk et al. (1982) have 
reported that fructose-2,6-P2 can protect rabbit 
liver and pig kidney FBPases against modification 
of the AMP site by pyridoxal-P. Han et al. (1991) 
have recently found that fructose-2,6-P2 can 
markedly reduce the rate of desensitization of 
turkey liver FBPase to AMP inhibition by 
butanedione. These data strongly suggest that the 
binding of fructose-2,6-P2 to FBPase significantly 
affects the reactivities of all the three 
essential amino acid residues (tyrosine, lysine 
and arginine) at the AMP allosteric site. 
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(j) Zn2+ is a very potent and specific metal inhibitor 
of FBPase (Nimmo and Tipton, 1975; Tejwani et al., 
1976). Based on the observations that Zn^ 
inhibition of FBPase activity can be reversed by 
histidine at concentrations found in rabbit liver 
under gluconeogenic conditions, Pedrosa et al. 
(1977) have proposed that Zn2+ and histidine may 
act together to modulate the levels of FBPase 
activity in liver. Han et al. (1978a) have 
subsequently reported that imidazole pyruvate, 
which may exist in about the same concentration as 
histidine in liver cells (White et al., 1973), is 
significantly more potent than histidine in 
reversing the inhibitory effect of Zn2+. 
(k) The effect of substrate and AMP on the reversal of 
Zn2+ inhibition of FBPase by chelators has been 
studied by Han et al. (1980). These researchers 
have found that the ability of chelators (EDTA, 
histidine, or imidazole pyruvate) to reverse Zn2+ 
inhibition of FBPase activity decreases greatly if 
substrate is first bound to the enzyme. If AMP is 
also present, chelators become almost completely 
incapable of reversing Zn2+ inhibition when added 
to the enzyme after substrate. These observations 
indicate that the prior binding of substrate to 
FBPase hinders the removal of Zn2+ from the 
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inhibitory sites of the enzyme by chelators, 
especially when AMP is also present. 
(l) Muscle FBPase is much more sensitive than liver 
FBPase to allosteric inhibition by AMP (Black et 
al., 1972; van Toi, 1974; Han et al., 1977a, 
1977b, 1982b). The concentration of AMP needed 
for 50% inhibition (KjJ of turkey muscle FBPase is 
approximately 100 times lower than that of turkey 
liver FBPase (Han et al., 1975, 1977a). 
(m) Although the inhibition of FBPase by excess 
substrate (fructose-1,6-P2) was reported by 
Mendicino and Vasarhely early in 1963, the 
mechanism for this inhibition is still poorly 
understood. Meek and Nimmo (1983) have suggested 
that high levels of fructose-1,6-P2 may inhibit 
FBPase by binding to an allosteric site (distinct 
from AMP site) . They have also suggested that 
fructose-2,6-P2 can also inhibit FBPase by binding 
to this allosteric site. Han et al. (1978b) have 
previously reported that treatment of chicken 
liver FBPase with acetylsalicylate desensitizes 
the enzyme to inhibition by excess substrate 
without significantly altering the activity and 
this desensitization can be prevented if treatment 
with acetylsalicylate is carried out in the 
presence of high concentration of substrate. It 
is possible that acetylsalicylate may selectively 
7 
alter the "fructose-1,6-P2 allosteric site." It 
is noteworthy that there has been no report so far 
demonstrating the binding of more than one 
molecule of fructose-1,6-P2 or fructose-2,6-P2 per 
subunit [see McGrane et al. (1983) for review]. 
Meek and Nimmo (1983) considered this might be 
only detectable at high levels of either fructose 
bisphosphate. They have, therefore, suggested 
that crystallographic studies may be needed to 
resolve this problem. 
(n) The activities of most FBPases at alkaline pH 
increase markedly upon limited proteolysis with 
subtilisin (Horecker et al., 1975; El-Dorry et 
al., 1977; Han et al., 1976). The increase in 
activity (about 5-fold) is accompanied by the 
cleavage of 60 residues from the NH2-terminal (El- 
Dorry et al., 1977; Fisher and Thompson, 1980; 
Marcus et al., 1981). 
(o) Recently, Vassarotti and Friesen (1985) have 
reported the isolation of the FBPase gene of yeast 
Schizosaccharomyces pombe. Their studies suggest 
that the regulation of FBPase gene is exerted at 
the transcriptional level. 
(p) A common feature of FBPase from various sources 
appears to be the presence of four highly reactive 
sulfhydryl (SH) groups per molecule of enzyme [for 
reviews see Chatterjee et al. (1984)]. Chatterjee 
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et al. (1984) have established that the highly 
reactive SH group is located at cysteine-128. 
According to these researchers, cysteine-128 is 
also present in FBPases from rat, sheep, and 
rabbit livers. This indicates that the region 
containing the most reactive cysteine residue 
appears to be highly conserved in FBPases. In 
contrast to a common phenomenon that most enzymes 
are inactivated by oxidation or modification of 
free SH groups [for reviews see Gilbert (1984)], 
modification of the highly reactive SH groups of 
FBPase cysteine-128 may markedly increase the 
catalytic activity. The compounds that were found 
to activate FBPase include iodoacetamide 
(Pontremoli and Horecker, 1970), p-mercuribenzoate 
(Pontremoli and Horecker, 1970), cystamine 
(Nakashima et al., 1969), oxidized CoA (Pontremoli 
et al., 1967), acyl carrier protein (Pontremoli et 
al., 1967), homocystine (Nakashima et al., 1970), 
iodoacetate (Zeidan et al., 1985 and 1986), and 
oxidized glutathione (Han et al., 1986). With 
these compounds, the increase in activity ranges 
from 3 to 13-fold. The one that induces the 
highest degree of activation (about 13-fold) is 
oxidized glutathione. Han et al. (1986) have 
recently reported that at the concentrations found 
in liver [about 0.2 mM (Gilbert, 1984)] the rate 
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of activation of FBPase by oxidized glutathione is 
very slow. However, the rate of activation 
increases markedly if treatment with this 
biological disulfide is carried out in the 
presence of AMP or Mn2+. It has been proposed by 
Nakashima et al. (1969) that FBPase may be under 
metabolic control by some biological disulfides, 
resulting in the enhancement of catalytic 
activity. 
(q) Research on immobilization of FBPase has so far 
attracted little attention. Falb et al. (1973) 
have previously reported the immobilization of 
FBPase to aminoethyl cellulose via glutaraldehyde. 
This immobilized enzyme retained only about 1% of 
the specific activity of the native enzyme. 
Recently Han et al. (1985) have reported the 
properties of FBPase immobilized on CNBr-activated 
Sepharose. The immobilized enzyme retained about 
38% of the specific activity of the native enzyme. 
Chemical Modification 
Chemical modification of proteins is one of the oldest 
chemical practices known to humanity, as it forms the basis 
of the ancient tailoring of foods and medicines for human 
consumption, as well as the dyeing, tanning and leather 
industries. Foods and medicines were characteristically 
prepared in earliest civilizations by mixing them with 
materials such as herbs, spices, acids, alkali, oils and 
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fermentation products (Feeney, 1986). The primary purpose 
of tanning is to improve the mechanical properties of raw 
hides while making them resistant to the action of 
degradative enzymes, microorganisms, and chemical agents 
such as water. The process whereby this is achieved is 
essentially one of cross-linking of peptide chains, formerly 
done with formaldehyde but now done also with 
glutaraldehyde, a crosslinking reagent commonly used in 
enzyme immobilization (Feeney et al., 1982). There are 
numerous other accounts of ancient chemical modifications 
that were carried out before the molecular nature of protein 
was understood. Other examples relate the use of alkali for 
the processing of fish to produce the stabilized product 
called lutfisk in Scandinavian countries and for the 
preservation of corn meal by the Mayan Indians of the 
southern United States, Mexico and South America (Feeney, 
1986). Some believe that when corn was first grown in 
Southern Europe and became a major factor in the diet there, 
pellagra became endemic in some areas because the crop had 
been imported without the cultural habit of alkali treatment 
that rendered it an effective staple food for the Mayan 
people (Feeney et al., 1982). 
Chemical modification of proteins was pursued more 
precisely early in the twentieth century as interest in the 
modification of proteins by means of a wide variety of 
specific chemical reagents rose sharply, paralleling the 
appearance of convincing evidence of the protein nature of 
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biologically important materials such as antigens, enzymes, 
toxins, some hormones and viruses (Herriott, 1947) (For 
excellent reviews of the topic see Cohen, 1968 and 1970; 
Freedman, 1971; Glazer, 1970; Herriott, 1947; Hirs, 1967; 
Hirs and Timasheff, 1972; Putnam, 1953; Riordan and 
Sokolovsky, 1971; Stark, 1970). The main focus of this 
pursuit of chemical modification was the analysis of the 
individual amino acids found to occur in proteins, until the 
work of many investigators, in particular Emil Fischer and 
his colleagues, worked on the synthesis and properties of 
small peptides. As attention increased on the occurrence 
and stabilization of various enzyme properties due to 
specific amino acid side-chains, the impetus increased for 
the study of the chemical modification of amino acid 
residues contained in various proteins (Feeney, 1977). 
"Enzymes represent a most remarkable set of 
biomolecules, owing both to their high catalytic activity 
and their ligand specificity. One of the important goals 
of biochemistry is to learn how enzymes perform their task, 
which is fundamental for the very existence of life" 
(Eyzaguirre, 1987). 
"Enzyme and substrates come in close contact in a 
limited area of the enzyme surface called the 'active site', 
at which the catalytic process takes place. To learn about 
the catalytic mechanism of an enzyme it is, therefore, 
essential to study the structural elements of this site 
(amino acid side-chains and prosthetic groups) and the 
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three-dimensional conformation of the site" (Eyzaguirre, 
1987). 
"The most powerful technique currently available for 
such a study is X-ray diffraction. If a diffraction 
pattern of sufficient resolution can be obtained, one can 
get a very accurate picture of the three-dimensional 
structure of the enzyme, and thus of its active site. With 
a good knowledge of the structural elements of the active 
site, a reasonable mechanism for their participation in the 
catalytic process can be deduced. 
"X-ray diffraction, however, suffers from some 
limitations. Among them are the need of obtaining the 
enzyme in a crystalline form adequate for the analysis. 
The technique is also very expensive and time-consuming and 
requires very specialized personnel and equipment. 
Besides, the question still remains to how valid are results 
obtained in the crystalline state when extrapolated to (that 
of an) aqueous solution (the condition under which enzymes 
operate). ... 
"A host of other analytical techniques, individually 
less powerful than X-ray diffraction, have been developed 
through the years to address structure questions. These 
techniques are important, not only as a means of 
complementing or confirming X-ray diffraction data, but can 
also give information of their own. Very often these are 
the only ways of probing active-site structure and function. 
These techniques include : chemical modification, nuclear 
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magnetic resonance, monoclonal antibodies, affinity 
labelling, fluorescence spectroscopy, photoaffinity 
labelling and photoaffinity crosslinking, etc." (Eyzaguirre, 
1987). 
Chemical modification, on its on power, can yield 
considerable information about an enzyme: 
a. stoichiometry of the enzyme modification reaction 
b. correlation of modification with biological property 
c. kinetic analysis of chemical modification 
d. enhanced peptide sequencing sensitivity and speed 
e. assignment of possible function to amino acids 
f. allosteric and cooperative properties 
g. assignment of tertiary location to amino acids 
h. establishing distances between functional groups 
i. alteration of enzyme specificity 
Numerous reagents with varying specificities for given amino 
acid residues have been used and cited in the literature and 
can be reviewed in the following references: Glazer et al. 
(1975); Glazer, (1976); Lundblad and Noyes, (1984). Only 
pertinent reagents used in the chemical modification of 
FBPase will be reviewed. 
In the specific case of FBPase, chemical modifications 
have been carried out at the AMP site using butanedione 
(Marcus, 1976; Riordan et al., 1977), acetylimidazole 
(Pontremoli et al., 1966), pyridoxal-P (Marcus and Hubert, 
1968; Krulwich et al., 1969; Colombo et al., 1972; Han et 
al., 1983), and acetylsalicylate (Han et al., 1978b). These 
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results suggest that arginyl, tyrosyl and lysyl residues are 
all present at the AMP allosteric site. Han and co-workers 
have recently shown that acetylsalicylate and pyridoxal-P 
may alter the AMP allosteric property of chicken and turkey 
liver (Han et al., 1991) by modifying the same lysyl 
residues at the AMP site. Frank Marcus reported that with 
butanedione modification FBPase catalytic activity remains 
unchanged while the enzyme becomes completely desensitized 
to AMP inhibition in 1.5 hours. Riordan et al., (1977), 
Fu-Kun et al., (1982) and Han et al., (1991) have all 
reported complete loss of AMP inhibition upon treatment of 
their FBPase with butanedione, suggesting the presence of 
arginyl residues at the AMP site of each enzyme. 
DeMaine and Benkovic (1980) reported that upon 
exhaustive formulation their rabbit liver FBPase lost all of 
its catalytic activity. However, this loss of activity did 
not occur all at once, but as it were in stages. 
Modification of 4-5 histidine residues of this enzyme 
occurred with no noticeable loss of activity. After the 
first 4-5 histidyl residues have been modified, a sharp loss 
of catalytic activity is observed. This loss of activity 
can be prevented by the inclusion of substrate in the 
modification mixture. Recently, Hunter and Han (unpublished 
results) have shown a very sharp decrease in catalytic 
activity of chicken liver FBPase when 10 mM 
diethylpyrocarbonate is incubated with the enzyme. 
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Pontremoli et al-, (1966 and 1969) have shown that 
alkaline rabbit liver FBPase has tyrosines that show three 
different reactivities to acetylation; two or three 
tyrosines that are rapidly acetylated, but not critical for 
any known enzyme property; four other tyrosines whose 
acetylation is associated with the loss of AMP inhibition; 
and the remaining four tyrosines whose modification is 
correlated with partial loss of the catalytic activity. 
Modification of the highly reactive SH groups of FBPase 
cysteine-128 has demonstrated the phenomenon of increase in 
the catalytic activity. Several laboratories have found 
that iodoacetamide (Pontremoli and Horecker, 1970), P- 
mercuribenzoate (Pontremoli and Horecker, 1970), cystamine 
(Nakashima et al., 1969), oxidized CoA (Pontremoli et al., 
1967), acyl carrier protein (Pontremoli et al., 1967), 
homocysteine (Nakashima et al., 1970), iodoacetate (Zeidan 
et al., 1985 and 1986), and oxidized glutathione (Han et 
al., 1986), give a 3 to 13-fold increase in the specific 
activity of FBPase. 
In our laboratory we are emphasizing the use of 
characterization through chemical modification as a tool to 
identify amino acid residues that are critical to an 
enzyme's function and, armed with this knowledge, to 
favorably alter the undesirable properties to achieve 
stabilization, resistance, and enhancement of enzyme 
activity. This new area of Enzyme Technology applies the 
biochemical information about the unique reactive residues 
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of each protein to maximize the protein's practical use in a 
biotechnological area. 
Immobilization 
In 1916, Nelson and Griffin reported that invertase 
extracted from yeast was adsorbed on charcoal, and the 
adsorbed enzyme showed similar activity as the native 
enzyme. In 1948, Sumner reported that urease from jack bean 
became water-insoluble on standing in 30% alcohol and sodium 
chloride for 1-2 days at room temperature, and the water- 
insoluble enzyme maintained enzyme activity. Further in 
1948 and 1949, Ephriam Katchalski prepared pole L-lysine 
(Katchalski, 1951; Katchalski and Bar-Eli, 1960; Katchalski, 
1962; Katchalski, 1969; for review see Katchalski, 1977), 
the first of many water soluble synthetic polyamino peptides 
he used in some of his earlier synthetic protein models. He 
later used these polyaminocopolymers to immobilize enzymes 
starting with trypsin in 1960 and 1963. Other accounts tell 
of Micheel and Ewers who (1949) used the azide derivative of 
carboxymethylcellulose to immobilize a variety of active 
proteins. However, it was not until Grubhofer and Schlieth 
(1953 and 1954) used a diazo derivative of poly-p- 
aminostyrene to immobilize pepsin, diastase, ribonucléase, 
amylase and carboxypeptidase, that any large-scale 
experimentation was carried out for the purpose of 
application in this field. With the work of Manecke in the 
1960s and his observation that the level of activity of an 
immobilized enzyme depends on the degree of hydration of the 
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polymer matrix, appeared the use of polymers other than 
cellulose for covalent bonding to enzymes (Manecke and 
Singer, 1960; Manecke, 1961; Manecke, 1962; Manecke and 
Gunzel, 1962; Manecke and Forster, 1966). 
A significant milestone occurred when instead of 
attaching the enzyme directly to the cellulosic or other 
polymer support a chemical "bridge" was used. The 
requirements for such a bridge was that it should be small 
and, once reacted with the polymer support, should have a 
group capable of being easily attached to the enzyme. Kay 
and co-workers (Kay and Crook, 1967; Kay and Lilly,1970) 
used cyanuric chloride as a bridge and immobilized 
galactosidase, lactate dehydrogenase, pyruvate kinase and 
creatine kinase, to cellulose. Another useful bridge 
molecule is glutaraldehyde, containing two aldehyde groups 
at the end of a (CH2)3 unit. 
The aldehyde groups react readily with amino groups at 
neutral pH. Thus one end can react with the support and one 
end to the enzyme functional group. Falb et al. (1973) 
reported the immobilization of FBPase to aminoethyl 
cellulose using glutaraldehyde. Their immobilized enzyme 
retained only about 1% of the specific activity of the 
native enzyme. The most common activation bridge in use 
today is that involving cyanogen bromide CNBr (See Axen et 
al., 1967; Porath, 1974). The actual way this molecule 
binds to the cellulose has not been ascertained, but 
apparently it reacts with the hydroxyl groups of 
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polysaccharides at high pH and the derivative then reacts 
with free amino groups on the enzyme in mildly alkaline 
solutions. Han et al. (1985) have reported the properties 
of FBPase immobilized on CNBr-activated Sepharose. This 
immobilized enzyme retained about 38% of the free enzyme's 
activity. 
At another level, Tosa et al. (1966) have been 
investigating immobilized enzymes with the goal of utilizing 
them for continuous industrial production. In 1969, they 
succeeded in the industrialization of the continuous optical 
resolution of DL-amino acids using immobilized aminoacylase 
(Chibata et al., 1972). This was the world's first report 
of an industrial application of an immobilized enzyme. 
Rapid development of studies and the application of 
immobilized enzymes have occurred in the United States, 
Europe and Japan since the 1960s. The term enzyme 
engineering has been used as a science and technology aimed 
at the efficient utilization of enzymes. In 1971, the 
first Enzyme Engineering conference was held in Henniker, 
New Hampshire and the major theme of the conference was 
enzyme immobilization. Enzyme immobilization is expected 
to result in several advantages over the free enzyme: 
1. Stability of enzymes is improved. 
2. A catalyst can be tailor-made for specific use. 
3. Enzymes can repeatedly reused. 
4. Continuous operation becomes practical. 
5. Reactions can be confined to less space. 
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6. Better control of the reaction is possible. 
7. Higher purity and yield of products may be obtained. 
8. Resources can be conserved and pollution minimized. 
(Chibata and Tosa, 1983) 
Many enzymes are being immobilized today using a 
variety of methods. The methods considered as 'state of the 
art' during the last 5 years are reviewed here. The 
simplest and most widely used method is adsorption and 
covalent coupling, the method we used in our research.. 
This method consists of mixing together the enzyme and 
support material under the appropriate conditions and 
following a period of incubation, separating the insoluble 
material from the soluble material by centrifugation and/or 
filtration. Many variations of this method are used and 
these are reviewed by Zaborsky (1973), Barker and Kay 
(1975), Goldstein and Mannecke (1976) and Mosbach (1976). 
Some of the support materials used for adsorption of enzymes 
are alumina, bentonite, calcium carbonate, calcium phosphate 
gel, carbon, cellulose, clay, collagen, concanavalin A- 
Sepharose, porous glass, hydroxyapatite, ion-exchange 
resins, Kaolin, phenolic polymers and silica gels. For the 
covalent attachment of enzymes, agarose (Sepharose), 
cellulose, dextran (Sephadex), glass, polyacrylamide co¬ 
polymers and polyaminostyrene are used. 
Another method of immobilization activates the support 
material by first chelating it with transition metal ions. 
The method was first developed by Novais (1971) when he 
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coupled diazo groups to cellulose prior to immobilization of 
the enzyme to this activated support. The original metal 
chelating method was applied mainly to polysaccharide 
supports as cellulose. Extension of this method to other 
inorganic and proteinaceous supports causes some problems 
regarding their use with the original technique. At the 
University of Birmingham, two alternative techniques were 
developed to achieve the precipitation of a hydrous metal 
oxide layer on non-porous solid lead glass beads by heating 
(Cardoso et al., 1978) and by neutralization (Kennedy et 
al., 1977 and 1979). The use of proteinaceous supports 
requires the use of very mild activation conditions that 
will result in minimum deterioration and inactivation of the 
delicate and sensitive matrix. Frequently, a cross-linking 
agent like glutaraldehyde is used to increase the 
operational stability of the immobilized enzyme matrix. 
Hydrous transition metal oxides (mainly titanium (IV) 
and zirconium (IV) have been used to immobilize enzymes and 
other biomolecules (Kennedy et al., 1975, 1976, 1977, 1978 
and 1981) as well as microbial cells (Kennedy et al., 1980). 
The immobilization of enzymes, biomolecules and cells on 
hydrous metal oxides is envisaged as a process involving the 
replacement of hydroxyl groups on the surface of the metal 
hydroxide, by suitable ligands from the enzymes, 
biomolecules or cells, resulting in the formation of partial 
covalent bonds. 
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Several methods involve the immobilization of enzymes, 
biomolecules and cells on various support materials by 
entrapment or encapsulation of these entities within a 
polymeric mesh such as polyacrylamide gel or calcium 
alginate (the major structural polysaccharide of marine 
brown algae) (Zaborsky, 1973; Chibata and Tosa, 1976; 
Abbott, 1976; Mosbach, 1976; Jack and Zajic, 1977; Durrand 
and Navarro, 1978; Venkatsubramanian, 1979; Trevan, 1980; 
Messing, 1980; Brodelius and Mosbach, 1982; Mattiasson, 
1982) . The polymerization and/or cross-linking reaction is 
carried out in the presence of the entity of interest. 
Since the polyacrylamide gel is made from toxic acrylamide 
and bisacrylamide monomers and heat is formed during gel 
polymerization, loss in viability of biomolecules and cells 
is a concern (Trevan and Grover, 1979; Freeman and 
Aharonowitz, 1981). In the presence of calcium and mild 
conditions, alginate forms a stable gel and has found its 
most extensive application in the entrapment of viable cells 
(Rees et al., 1982; Kierstan and Bucke, 1977). Other 
methods of entrapment utilize carrageenans (heterogeneous 
polysaccharides containing predominantly alpha-D- 
galactopyranosyl sulphate esters) (Tosa, et al., 1979; Wang 
and Hettwer, 1982), agar (Matsunaga et al., 1980), collagen 
(Constantinides, 1980) and cellulose (Linko, et al., 1978). 
A great deal of current research deals with controlled 
drug release from microcapsules (Chang, 1977a and 1977b; 
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Patwardhan and Das, 1983). Microencapsulation focuses on 
maintaining the solution environment around the enzyme, 
biomolecule or cell, rather than upon maintaining the 
physical or chemical forces necessary for immobilization. 
Microencapsulation creates artificial cells which have a 
membrane similar to natural cells, to control the size of 
molecules which may enter or leave this artificial cell. 
The method allows large molecules, enzymes, proteins, or 
even cells to be retained within an encapsulated sphere, 
while small substrate and product molecules can freely 
diffuse across the synthetic membrane. Some advantages of 
this method are the high surface area possible per unit of 
enzyme immobilized, high concentration of enzyme in the 
artificial cell, and a variety of enzymes, cells and/or 
biomolecules could be simultaneously encapsulated to allow a 
multi-step reaction to proceed. Even though the concept of 
forming a synthetic polymeric membrane around an enzyme or 
biomolecule to make a microsphere is rather appealing and 
seems to be simple, in practice a great deal of technology 
is needed to make the spheres uniform and to impart high 
activity retention. Some of the synthetic polymers used as 
a membrane for encapsulation are polyethyleneimine (PEI)- 
nylon, cellulose nitrate and epoxy (Chang, 1977a and 1977b; 
Grunwald and Chang, 1981), cellulose acetate butyrate 
(Gardner and Emmerling, 1977), cellulose nitrate (Mangensen 
and Vieth, 1973; Wadiak and Carbonell, 1975; Chang, 1977a 
and 1977b; Artmanis et al., 1984), lipid-polyamide (Yu and 
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Chang, 1982) , nylon (O'Grady and Joyce, 1981) , 
poly(phthaloyl piperazine) (Kondo and Muramatsu, 1976), and 
several water soluble polymers including bovine serum 
albumin (BSA), polyvinyl pyrolidone (PVP), polyvinyl alcohol 
(PVA), polyethylene glycol (PEG), dextran and sodium 
heparinate (Yanagibashi et al., 1979). 
The enzyme electrode is a combination of an ion- 
selective electrode base sensor with an immobilized 
(insolubilized) enzyme, which provides a highly selective 
and sensitive method for determining a given substrate. 
Since the introduction of the concept by Clark and Lyons 
(1962) and the first working model reported by Updike and 
Hicks (1971), over 100 different electrodes have been 
reported in the literature. Of the two methods used to 
immobilize an enzyme onto an electrode, (a) the chemical 
modification of the molecules by the introduction of 
insolubilizing groups, and (b) the physical entrapment of 
the enzyme in an inert matrix, the technique of chemical 
immobilization yields the best electrode probes. Of those 
electrode types reviewed by Guilbault (1984), are included 
those that are sensitive to urea, glucose, L-amino acids 
(general), L-tyrosine, L-glutamine, L-glutamic acid L- 
asparagine, D-amino acids (general), lactic acid, succinic 
acid, acetic acid, formic acid, alcohols, penicillin, 
cholesterol, nitrate, nitrite, sulphate, uric acid, 
phosphatase and amygdalin. In addition, biological probes 
have been used to bind whole cell microorganisms or tissue 
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cells to the surface of an ion-selective electrode (Divies, 
1975 and 1976). Another application of biological probes 
is the construction of sensor probes utilizing bound 
antigens or antibodies (Suzuki, 1979). It is quite 
apparent that numerous biological molecules are being 
immobilized on a variety of support materials and the 
numbers are steadily increasing, being limited only by the 
need and imagination of the researcher or practitioner. 
As the areas of agriculture, medicine and industry 
experience an increasing need for specific immobilized 
enzyme products, research and development in molecular 
biology and biotechnology are being prompted and even 
demanded to develop practical methods of meeting these 
societal needs. The applications are almost unlimited, 
starting with the stabilization of unstable or labile 
enzymes in clinical analyses (Wiseman, 1985), to the 
development of different enzyme electrodes (Wiseman, 1985), 
to the use of immobilized enzymes in organic chemical 
reactions (Miura et al., 1975; Shimuzu et al., 1975; Wong et 
al., 1981 and 1982), to the conservation of restriction 
endonucleases (Chirikjian, 1982), to the enhancement of the 
quality and quantity of food (Linko et al., 1975; Beynum et 
al., 1980; Lee et al., 1976; Daniels and Farmer, 1981; 
Poulsen et al., 1980; Walon, 1980; Takasaki and Takahara, 
1974; Bucke and Wiseman, 1981; Pastore et al., 1974; Cheryan 
et al., 1975; Swaisgood, 1977, 1978 and 1980; Takamatsu et 
al., 1982; Middlehoven and Bakker, 1982; Gestrelius and 
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Kjaer, 1983; Hasegawa et al., 1982; Hasegawa and Pelton, 
1983) , to the detoxification of toxins (Klibanov and Morris, 
1981; Nazaly and Knowles, 1981; Livernoch et al., 1981; Kirk 
and Yang, 1979; Mattiasson et al., 1981; Hackel et al., 
1975) , to manufacture of paper (Clayton et al., 1984), to 
production of antibiotics (Morikawa, 1980; Lagerlof et al., 
1976; Fuji et al., 1973; Deo and Gaucher, 1983; Abbott, 
1976) , to amino acid production (Nakanishi et al., 1981 and 
1982; Swann, 1984; Anderson et al., 1984), and to the 
production of biosensors (Gronow, 1984). The first 
industrial use of an immobilized enzyme in the United 
States, and one of the largest commercial uses of an 
immobilized enzyme today, was the isomerization of glucose 
in high-glucose corn syrup by immobilized glucose isomerase 
(MacAllister, 1980). In the dairy industry, the "cooked" 
taste of processed milk can be completely removed with 
immobilized sulfhydryl oxidase (Swaisgood, 1980; Swaisgood 
et al., 1982) and trypsin immobilized on porous silica can 
remove the oxidized flavor from stored milk (Lee et al., 
1975). 
A limitation to the therapeutic use of proteins as 
enzymes in the treatment of various diseases is the 
formation of antibodies and anaphylactic shock and/or 
inactivation of the enzyme by immunological reactions. 
Enzyme immobilization has been used in attempts to 
circumvent these problems in several ways. Some 
experimental uses of immobilized enzymes in clinical 
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settings are (1) enzyme replacement therapy for hereditary 
enzyme-deficiency conditions (Chang and Poznansky, 1968; 
Chang, 1972b; Poznansky and Chang, 1974; Gregoriadis and 
Ryman, 1972; Ihler et al., 1973; Thorne et al., 1975); (2) 
asparaginase for substrate-dependent tumor suppression 
(Chang, 1969a, 1971, 1972a, 1973a and 1973b; Updike et al., 
1973; Mori et al., 1972 and 1973; Siu Chong and Chang, 1974; 
Ohnuma et al., 1973; Horvath, 1973; Sampson et al., 1972; 
Hersh, 1974; Cooney et al., 1975; Venkatasubramanian et al., 
1974) ; (3) immobilized enzymes and proteins in organ failure 
(Chang, 1966, 1969b, 1972a and 1975; Levin and LaCourse, 
1967; Gordon et al., 1969; Chang and Loa, 1970; Broun et 
al., 1970; Sparks et al., 1971; Gardner et al., 
1971; Kusserow et al., 1971 and 1973; May and Li, 1972; 
Bessman and Schultz, 1973; Venter et al., 1975; Asher et 
al., 1975) and (4) basic models for enzyme therapy (Chang 
and Macintosh, 1964; Chang, 1964, 1966, and 1972a; Venter et 
al., 1975). Other research directions for immobilized 
enzymes deal with the development of monoclonal antibodies 
specific for given effector sites on the enzyme (Nilsson et 
al., 1983). With adequate knowledge of the reactive amino 
acid residues of an enzyme, critical effector sites of an 
enzyme may be bound, left free or replaced to produce the 
desired antibody.. 
With these and other applications, the enzyme is seen 
as a molecule that can undergo organic manipulations just as 
less complex chemicals can. Enzyme technology focuses on 
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the application of scientific organic and engineering 
principles to the enzyme molecule to enhance its desirable 
properties and applications. One of the main objectives of 
this study is to develop unique techniques for preparation 
of highly active immobilized FBPase by attaching the enzyme 
to the appropriate carriers using the epsilon amino group of 
lysyl residues at the AMP allosteric site or the highly 
reactive sulfhydryl groups of cysteine-128. The other 
objective of this study is to use techniques of chemical 
modification to elucidate the essential functional groups 
and to enhance the desirable catalytic properties such as 
increasing the enzyme's specific activity, enhancing it's 
resistance to proteolytic digestion, and selectively 
desensitizing the enzyme to inhibition by fructose-2,6- 
bisphosphate. In addition to its contribution to the field 
of FBPase research, it is believed that this study may yield 
some information valuable to the field of enzyme technology 
which is becoming more important not only in industry but 
also in various branches of medicine. 
CHAPTER II 
OBJECTIVES, RATIONALE AND APPROACH 
Objectives 
A. To investigate the functional consequences of modifying 
FBPase with butanedione (an arginine-specific reagent) 
and diethylpyrocarbonate (a histidine-specific 
reagent). 
B. To investigate whether activation of FBPase by oxidized 
glutathione (over 13-fold) is accompanied by alteration 
of other catalytic properties. 
C. To prepare highly active immobilized FBPase by 
attaching the enzyme to the appropriate carriers using 
the epsilon-amino groups of lysyl residues at the AMP 
allosteric site or the highly reactive sulfhydryl 
groups of cysteine-128. 
D. To prepare radioactively labelled FBPase that is still 
highly active or more active than the native enzyme. 
Rationale and Approach 
A. Rationale 
Three different laboratories using FBPase from 
different sources have reported conflicting results upon 
modification of their enzyme with the arginine-specific 
reagent, 2,3-butanedione. James F. Riordan's group (Riordan 
et al., 1977) used rabbit muscle FBPase and Zhao Fukun's 
28 
29 
group (Fu-kun et al., 1982) used the enzyme from snake 
muscle, showing loss of catalytic activity and desensitiza¬ 
tion to AMP inhibition upon modification of their respective 
enzymes with butanedione. Frank Marcus' group (Marcus, 
1976) used FBPase from rabbit liver and pig kidney and upon 
modification with butanedione, also saw desensitization to 
AMP inhibition. This group noticed no change in catalytic 
activity, but a loss of K+ activation due to butanedione 
modification. Zhao Fu-kun's (Fu-kun et al., 1982) group 
observed an increase in catalytic activity and AMP 
inhibition due to K+ ion presence. The modification did not 
alter these two properties. The catalytic function and the 
maintenance of K+ activation during modification with 
butanedione, are reported in contradiction. Since this 
laboratory has worked with chicken liver FBPase, we 
investigated the behavior of this enzyme following 
modification with butanedione. 
When rabbit liver FBPase was ethoxyformylated by De 
Maine and Benkovic (1980), they did not see a sharp loss of 
activity until 4 or 5 of the 13 histidine residues had 
reacted. Since not much work has been published on the 
modification of histidine in neutral FBPase, we investigated 
the functional consequences of modifying neutral FBPase from 
chicken liver with diethylpyrocarbonate. 
Approach 
The catalytic and allosteric properties of the 
butanedione and diethylpyrocarbonate modified FBPase was 
30 
followed progressively using a modification of an enzyme 
coupling assay first developed by Mendicino and Vasarhely. 
The relative activity of the control was compared to that of 
the modified enzyme in the presence and absence of various 
effectors such as KCl, 5'AMP, F-2,6-P2 and F-l,6-P2. The 
effector sites on the enzyme were further characterized by 
carrying out protection studies with F-2,6-P2, AMP, and F- 
1,6-P2 in the incubation mixtures and comparing the relative 
activities of the modified FBPase as they changed with time. 
B. Rationale 
This laboratory has reported recently that FBPase, 
incubated with oxidized glutathione is activated over 13- 
fold (Han et al., 1986). The phenomenon is further 
highlighted since most sulfhydryl-containing enzymes are 
inactivated by oxidation or modification of their free SH 
groups. There is also a possibility that this enzyme, as 
well as many others, may be under metabolic regulation by 
thiol/disulfide exchange (Gilbert, 1982 and 1984). 
Considering the possible physiological significance of 
this type of modification with oxidized glutathione, we 
investigated whether this activation of catalytic activity 
is accompanied by the alteration of other properties of the 
enzyme. 
Approach 
The enzymes were incubated with oxidized glutathione in 
the appropriate buffer solution and aliquots were removed to 
examine whether any altered properties had occurred. These 
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included AMP inhibition, K+ activation, F-2,6-P2 inhibition, 
high substrate inhibition, K+ activation, F-2,6-P2 
inhibition, high substrate inhibition, resistance to the 
proteolytic enzymes, subtilisin and trypsin, the number of 
SH groups reacting with dithionitrobenzoic acid and 
iodoacetamide/iodoacetate. The modified enzyme's relative 
activity was compared to that of the control in the presence 
of the appropriate effectors mentioned above. 
C. Rationale 
One of the common features of FBPase is its allosteric 
inhibition by AMP and this inhibition can be selectively 
desensitized without significantly affecting the catalytic 
activity, by treatment of the enzyme with pyridoxal-P (PL-P) 
in the presence of substrate followed by reduction with 
NaBH4 (Ryan, 1972). This indicates that the enzyme contains 
a reactive lysyl residue at the AMP allosteric site. Another 
common feature of FBPase is the presence of a single highly 
reactive SH group per mole of enzyme subunit and 
modification of this SH group by several sulfhydryl and 
disulfide reagents results in marked increase in catalytic 
activity, we used the above mentioned specific lysine or 
cysteine residues to develop specific and unique techniques 
for immobilization of chicken liver FBPase. In character¬ 
izing avian liver FBPases, Han and co-workers have invest¬ 
igated the reactive lysyl residues and the highly reactive 
SH groups. Modification of the lysyl residues at the AMP 
allosteric site does not inhibit the catalytic activity of 
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FBPase. In fact, modification of the enzyme with lysine- 
specific reagents results in an increase in the relative 
activity, reported to be due to the relief of high substrate 
inhibition. The modification of the enzyme with disulfide 
reagents also results in a sharp increase in the enzyme's 
catalytic activity. Having thoroughly characterized the 
reactive lysyl epsilon-amino groups at the AMP site and the 
highly reactive cysteinyl residues, these groups served as 
excellent sites for the attachment of FBPase to suitable 
carriers. 
Approach 
Since FBPase undergoes thiol/disulfide exchange in vitro, we 
immobilized this enzyme on cystamine-Sepharose, a disulfide 
containing carrier, by thiol/disulfide exchange at the 
highly reactive cysteine residues. FBPase was also 
immobilized onto a PL-P-Sepharose derivative by attachment 
to the epsilon-amino groups of lysyl residues at the AMP 
site. For this approach, substrate was included in the 
incubation mixture to protect the lysyl residues near the 
catalytic site from being attached to the carriers. The PL- 
P analog that was used was the 6-immobilized PL-P analog 
kindly prepared by Dr. Grace Han of Morehouse College. 
Immobilization on the above PL-P-Sepharose analog is 
expected to result from the formation of a Schiff base 
linkage between the 4-formyl group of the bound PL-P and the 
epsilon-amino group of a lysine residue at the AMP 
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allosteric site. The Schiff base is suggested to be 
stabilized by reduction with NaBH4 (Ryan, 1972). 
D. Rationale 
Not every theoretical modification actually resulted in 
the desired immobilized enzyme with increased activity. To 
determine which immobilized enzymes fitted the desired 
characteristics, each was studied and tested for specific 
desired uses. The immobilized enzyme may be used to carry 
out several enzymatic tasks. But to be sure that the 
desired function was not impaired by the enzyme 
immobilization, the immobilized enzyme was tested for the 
specific tasks for which it was to be used. The immobilized 
FBPase may be employed to selectively hydrolyze fructose- 
1, 6-bisphosphate during the chemical synthesis of fructose- 
2, 6-bisphosphate, to study FBPase subunit hybridizations, to 
isolate FBPase antibody and to produce highly purified 
fructose-6-phosphate. 
Approach 
FBPase was radioactively labelled with [3H]-acetic 
anhydride or [14C]-iodoacetamide. The acetylation of 
exposed lysyl residues of FBPase was carried out in the 
presence of AMP and substrate to assure that the reactivity 
of the SH groups was greatly suppressed. At various times 
during the reaction, aliquots were removed and, after 
repeated precipitation of FBPase with ammonium sulfate (80% 
saturation), the specific activities, with respect to both 
enzyme activity and radioactivity, were determined. 
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The reactive SH groups were labelled by treating FBPase 
with [14C]-iodoacetamide in the presence of Mn+2 and AMP. 
The reaction was allowed to proceed for 12 hours and then 
the ammonium sulfate precipitate was collected and 
extensively dialyzed with the appropriate buffers to remove 
AMP, MnCl2 and excess iodoacetamide. The procedure resulted 
in the labelling of the reactive cysteine-128 with a 
concomitant considerable increase in specific activity. 
CHAPTER III 
MATERIALS AND METHODS 
Materials 
Fresh chicken livers were kindly provided by Fieldale 
Farms, Bartow, Georgia, or Seaboard Farms, Canton, Georgia. 
Fructose-1,6-bisphosphate, fructose-2,6-bisphosphate, 2,3- 
butanedione, diethylpyrocarbonate, 5'AMP, MgCl2, NAD, NADP, 
MnCl2, cysteine, phosphoglucose isomerase, CNBr-activated 
Sepharose 4B and 6MB, oxidized glutathione, iodoacetamide, 
iodoacetate, 5,5'-dithiobis-(2-nitrobenzoic) acid (DTNB), 
ammonium sulfate, NaBH4, Trizma base, boric acid, EDTA, and 
acetylsalicylic acid were purchased from Sigma Chemical 
Company, St. Louis, Mo, USA. Leuconostoc mesenteroides 
glucose-6-phosphate dehydrogenase was obtained from Toyoba 
Shinko American, Inc., N. Y., N. Y.. Whatman phosphocell- 
ulose (P-cellulose) was purchased from H. Reeve Angel, Inc., 
Clifton, N. J.. Acetic anhydride ([3H]-(CH3CO)20 
(50mCi/mmol)) and iodoacetamide ([1-14C]-ICH2CONH2 (10- 
25mCi/mmol in ethanol)) were purchased from New England 
Nuclear Research Products, Boston, Ma. 
Methods 
FBPase was purified from chicken livers as previously 
described (Han et al., 1976; Han and Johnson, 1982). 
FBPase activity was determined by the coupling method of 
Mendicino and Vasarhely (1963) with a modification as 
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described by Han et al. (1986). In this modified method, 
yeast glucose-6-phosphate dehydrogenase was replaced by 
Leuconostoc mesenteroides glucose-6-phosphate dehydrogenase, 
so that NADP could be replaced by the relatively less 
expensive NAD. The standard assay mixture (1 ml) contained 
50 mM Tris-HCl buffer (pH 7.5), 0.05 mM EDTA, 0.2 mM MnCl2 
or 5 mM MgCl2, 0.25 mM NAD, 0.2 mM fructose-1,6-bisphosphate 
(F-l,6-P2), 1 unit each of phosphoglucose isomerase and 
glucose-6-phosphate dehydrogenase and an appropriate amount 
of FBPase. Unless otherwise stated, all assay components 
except FBPase were mixed together and the reaction was 
initiated by the addition of FBPase. The increase in 
absorbance at 340 nm was continuously monitored for 5 min at 
25°C and the linear portion of the initial rate was used for 
calculation of FBPase activity. In nearly all cases, the 
duplicate assays did not vary more than 6%. The 
concentration of the purified enzyme was determined by its 
absorbance at 280 nm using the extinction coefficient 
(1 mg/ml; a 1 cm light path) of 0.71 (Han and Johnson, 
1983). Specific activity was defined as units/mg protein. 
One unit of FBPase activity was defined as the amount that 
caused the formation of 1 /xmole of NADH under the standard 
assay conditions. The standard assay mixture (1 ml) for 
the activity of immobilized FBPase contained 50 mM Tris-HCl 
buffer (pH 7.5), 0.05 mM EDTA, 0.2 mM MnCl2, and 0.2 mM (F- 
1,6-P2). The reaction was initiated by the addition of an 
appropriate amount of immobilized FBPase and was carried out 
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with gentle shaking at 25°C in a 1.5 ml Eppendorf centrifuge 
tube. After 5 min, the reaction was terminated by the 
addition of 1 mM EDTA and followed by centrifugation to 
precipitate the resin. The addition of excess EDTA was to 
chelate all of the free Mn2+ which is absolutely essential 
for FBPase catalytic activity. The amount of fructose-6-P 
formed during the reaction period was determined by the 
increase in absorbance at 340 nm after addition of 0.3 mM 
NAD and 1 unit each of glucose-6-P dehydrogenase and 
phosphoglucose isomerase. 
The amount of FBPase bound to pyridoxal-P-Sepharose was 
determined by the difference between the initial amount of 
enzyme added and the amount of enzyme remaining free in the 
supernatant fluid after the coupling process was stopped. 
To determine the amount of FBPase bound to cysteamine- 
Sepharose, the enzyme was first released from the resin by 
treatment with 5 mM DTT for at least 1 hour. Protein 
concentration was then determined by the method of Lowry et 
al. (1951) using purified FBPase as the standard. 
Chemical modification of FBPase with GSSG, iodoacet- 
amide, iodoacetate, butanedione, and diethylpyrocarbonate 
was carried out as described in the legend to the respective 
tables and figures. 
Sulfhydryl groups of FBPase were determined by 
measuring spectrophotometrically at 412 nm, samples titrated 
with 50 juM DTNB in 60 mM Tris-HCl buffer (pH 7.5) with or 
without 8 M urea. A molar extinction coefficient of 13,600 
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for the liberated thionitrobenzoate anion was used for all 
calculations (Ellman, 1959). 
Immobilization of FBPase 
FBPase was immobilized by the following methods: 
(a) Immobilization of FBPase by attaching the enzyme to a 
pyridoxal phosphate (PLP)-Sepharose derivative using the Ÿ- 
amino group of the lysyl residue at the AMP allosteric site. 
PLP-Sepharose immobilized at the 6 position (structure shown 
below) was provided by Dr. Grace Y. Han of Morehouse 
College. It was prepared according to the methods of Ikeda 
and Fukui (1973) and Ikeda et. al. ( 1974 ). Unless 
otherwise stated, immobilization of FBPase on PLP-bound 
Sepharose was carried out as follows: wet PLP-bound 
Sepharose (about 0.5 g) was mixed with 1.5 mg of FBPase in 
2.0 ml of 50 mM sodium borate buffer (pH 8.0) containing 4 
mM F-l,6-P2 and 0.1 mM EDTA. The reaction mixture was 
incubated at 25°C with gentle shaking for 30 to 40 min. The 
resulting FBPase-PLP-Sepharose was reduced with NaBH4 as 
previously described (Han et al., 1983). The fluid was 
removed by gentle vacuum filtration and the immobilized 
enzyme was thoroughly washed with 50 mM Tris-HCl buffer (pH 
7.5) containing 0.1 mM EDTA. Immobilization of FBPase on 
PLP-bound Sepharose is expected to result from the formation 
of a Schiff base linkage between the 4-formyl group of the 
bound PLP and the epsilon-amino group of a lysyl residue at 
the AMP allosteric site of FBPase. The Schiff base is then 
stabilized by reduction with NaBH4, as shown below: 
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Since the epsilon-amino groups of lysyl residues at the 
AMP allosteric site are highly reactive with respect to 
forming Schiff-bases with PLP and these reactions do not 
affect the catalytic activity significantly, the coupling 
process occurred readily, yielding active immobilized 
FBPase. To unequivocally confirm that the lysyl residues at 
the AMP site were used for the attachment, a control 
experiment was conducted in each case to determine that the 
inclusion of AMP (1 mM) in the reaction mixture prevented 
the immobilization of FBPase on the PLP-Sepharose analogue, 
(b) Immobilization of FBPase by Thiol/Disulfide exchange 
with Cystamine-Sepharose (structure shown below). 
Cystamine-Sepharose -NH-CH2-CH2“S-S-CH2-CH2-NH2 
Cysteamine-Sepharose -NH-CH2-CH2-SH 
Cysteamine-Sepharose was prepared with some modifications of 
the method of Seelig and Meister (1982). CNBr-activated 
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Sepharose (5 g) was swollen in 200 ml of distilled water. 
It was then washed for 15 min on a filter paper with 300 ml 
of 1 mM HC1. The gel was washed thoroughly with 0.1 M 
NaHC03 (pH 7.9) containing 0.5 M NaCl (coupling buffer). 
An excess of cystamine (4 g) was dissolved in coupling 
buffer and mixed in a flask with the CNBr-activated 
Sepharose. The flask was shaken gently at 4°C overnight. 
Excess ligand was washed from the gel with 1 liter of 
coupling buffer, and any remaining unreacted groups were 
blocked by incubation with 1 M ethanolamine (pH 9.0). The 
gel (about 20 ml) was then washed thoroughly with coupling 
buffer and stored at 4°C until use. The amount of 
cystamine bound was estimated to be about 2 /nmol/ml after 
reduction with DTT followed by reaction with DTNB. 
Thiol/disulfide exchange of FBPase with cystamine- 
Sepharose was carried out as follows: Moist resin was added 
to 20 ml of coupling buffer containing 0.2 mM EDTA, and 24 
mg of purified FBPase. The reaction mixture was incubated 
at 25°C with gentle shaking for 3 h and the fluid was then 
removed by vacuum filtration. The resin was washed on 
filter paper with 300 ml of coupling buffer. 
CHAPTER IV 
RESULTS 
Modification of FBPase with Oxidized Glutathione (GSSG) 
This study has confirmed the previous report that 
treatment of chicken liver FBPase with GSSG leads to a 
marked increase (over 13-fold) in specific activity (Han et 
al., 1986). Since activation of FBPase by GSSG may play a 
role in the regulation of this enzyme, attempts have been 
made to investigate whether this activation is accompanied 
by the alteration of other catalytic properties. 
Figure 1 shows that treatment with GSSG resulted in a 
marked decrease in the sensitivity of the enzyme to 
inhibition by fructose-2,6-bisphosphate. The concentration 
needed for 50% inhibition of activity (K^) was about 1.5 /LIM 
for the native or untreated enzyme, while at that same 
concentration of this inhibitor greater than 90% of the 
activity of the GSSG-treated enzyme still remained. In the 
presence of 4 /iM fructose-2,6-bisphosphate, about 80% of the 
activity still remained for the treated enzyme, while the 
native enzyme retained only about 5% of the activity under 
the same assay conditions. 
Figure 2 shows that treatment of FBPase with GSSG 
resulted in an increase in the sensitivity of this enzyme to 
inhibition by Zn2+, a specific and very potent inhibitor of 
this enzyme. The for this metal inhibitor is estimated 
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Fig. l. The Inhibition of GSSG-Treated and Native FBPase 
By F-2,6-P2• The native and GSSG-treated FBPases 
were prepared according to the procedures as 
described in the Materials and Methods. A 
solution containing 0.8 units (/zmoles/min) /mg of 
native and GSSG-treated FBPase was prepared in 0.1 
M Tris-HCl buffer (pH 7.5). Identical aliquots of 
each enzyme (20 /zl) were assayed in the presence 
of the indicated amount of F-2,6-P2 under the 
standard assay conditions as described in the 
Materials and Methods except that the substrate 
concentration was 20 /zM. The relative activity of 
100 is equivalent to the specific activity 
(units/mg) of 12.8 for the native FBPase or 132.2 
for the GSSG-treated enzyme. 


















FBPase By F-2,6-P2. 
Fig. 2. The Inhibition of GSSG-Treated and Native FBPase 
by ZnCl2< The native and GSSG-treated FBPases 
were prepared according to the procedures in the 
Materials and Methods. A solution containing 0.8 
units (/xmoles/min) /ml of native or GSSG-treated 
FBPase were prepared in 0.1 M Tris-HCl buffer (pH 
7.5). Identical aliquots of each enzyme (20 nl) 
were assayed in the presence of the indicated 
amount of ZnCl2 under the standard assay 
conditions as described in the Materials and 
Methods. The relative activity of 100 is 
equivalent to the specific activity (units/mg) of 
9.2 for the native enzyme or 128.2 for the GSSG- 
treated FBPase. 
Solid circles = GSSG-treated enzyme, Open circles 

















Fig. 2. The Effect of 2nCI2on Natiue and 
GSSG-Treeted FBPase. 
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to be 0.45 /JM for the native enzyme, compared with 0.25 MM 
for the GSSG-treated enzyme. 
Figure 3 shows that treatment with GSSG renders the 
enzyme more resistant to inactivation by the proteolytic 
enzyme, trypsin. The time needed for 50% decrease in 
activity (ti/2) 
was estimated to be 18 min for the native 
enzyme, compared to 42 min for the GSSG-treated enzyme under 
the same experimental conditions as described in the legend 
to this figure. 
Fructose-2,6-bisphosphate was found to provide the 
native FBPase with significant protection against 
inactivation by trypsin. Under the conditions as described 
in the legend to Table 1, the t^/2 f°r the native enzyme was 
estimated to be 18 or 105 min when digestion with trypsin 
was carried out in the absence or presence of 0.5 mM 
fructose-2,6-bisphosphate, respectively. Although FBPase 
becomes more resistant to trypsin inactivation after 
modification with GSSG (Figure 3), the modified enzyme was 
only slightly responsive to the protective effect of 
fructose-2,6-bisphosphate against inactivation by trypsin. 
Also as shown in Table 1, the t^/2 for the GSSG-treated 
enzyme was 42 or 46 min when digestion with trypsin was 
carried out in the absence or presence of 0.5 mM fructose- 
2,6-bisphosphate, respectively. 
Fig. 3 Inactivation of Native, Aspirin-Treated and GSS6- 
Treated FBPases By Trypsin. The native, GSSG- 
treated and aspirin-treated FBPases were prepared 
according to the procedures as described in the 
Materials and Methods. Solutions containing 0.8 
units/ml of each of these enzymes were prepared in 
0.1 M Tris-HCl buffer (pH 7.5). An equivalent 
volume of trypsin dissolved in 0.1 M Tris-HCl 
buffer (pH 7.5) at a concentration of 0.5 mg/ml, 
was mixed with each enzyme solution and aliquots 
of each were removed at the times intervals 
indicated and assayed for enzyme activity under 
the standard assay conditions as described in the 
Materials and Methods . The relative activity of 
100 is equivalent to the specific activity 
(units/mg) of 9.2 for the native enzyme, 8.8 for 
the aspirin-treated enzyme, or 128.2 for the GSSG- 
treated enzyme. 
Solid circles = GSSG-treated enzyme, Open circles 




















Fig. 3. Inactiuation of Natiue, Aspirin-Treated 
and GSSG-ïreated FBPases By Trypsin. 
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Table 1. Effect of Fru-2,6-P2 on the Inactivation of Native 
and GSSG-Treated FBPase by Trypsin 
Time required for 
Enzyme Addition 50% inactivation (TI/2) 
Native None 18 minutes 
Native Fru-2,6-P2 (0.5 mM) 105 minutes 
GSSG-Treated None 42 minutes 
GSSG-Treated Fru-2,6-P2 (0.5 mM) 46 minutes 
The Native and GSSG-Treated FBPase (0.2 mg/ml or 1.4 nM) 
were incubated with 0.5 mg/ml of trypsin in the absence and 
presence of 0.5 mM Fru-2,6-P2. Aliquots were taken at 
various time intervals and assayed for residual activity as 
described in the Materials and Methods section. The 
relative activities and the time required for 50% 
inactivation (Ti/2) were determined based on 100% relative 
activity taken as 9.2 and 132.2 /^mole/minute/milligram for 
the uninhibited native FBPase sample (control) and the GSSG- 
treated FBPase, respectively. 
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The data in Table 2 show that treatment with GSSG did 
not alter the sensitivity of the enzyme to AMP inhibition. 
When 20 nM AMP was included in the assay mixtures, the 
native and GSSG treated FBPaseshowed 62% and 68% inhibition, 
respectively. When 60 juM AMP was included in the assay 
mixtures, the enzymes showed 92% and 96% inhibition, 
respectively. 
Incubation of the native enzyme with 50 juM dithionitro- 
benzoic acid (DTNB), showed that 4 SH groups per molecule of 
enzyme were titratable. These 4 reactive SH groups were no 
longer detected after the enzyme had been treated with GSSG 
for 24 h. The total number of SH groups per molecule of 
FBPase titrated with DTNB in 8 M urea was found to be 24.3 
and 20.6 for the native and the GSSG-treated enzyme, 
respectively. 
Also, as shown in Table 2, the specific activities 
(/xmoles/min/mg) of the native and GSSG-treated enzymes were 
determined to be 9.2 and 125, respectively. The ratio of 
the enzyme activities at pH 7.5 and 9.2, were 2.2 and 2.0 
for the native and GSSG-treated FBPase, respectively. The 
native enzyme in the presence of 150 mM KC1 was activated 
120% above the control, whereas the GSSG-treated enzyme was 
not activated. 
GSSG treatment also resulted in the dramatic 
reactivation of a 2-1/2 year old FBPase preparation (Table 
3). The specific activity of the 854 day old enzyme 
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Table 2. Comparison of Some Properties of the Native and 
GSSG-Treated FBPases 
Native GSSG Treated 









% Increase by 150 mM 
KC1 
120 0 
Total SH Groups/Molecule 
Titrated With DTNB 
(A) + 8M Urea 24.4 20.3 
(B) - 8M Urea 4.2 0.3 
% Inhibition by 
(A) 2OuM AMP 62 68 
(B) 6OuM AMP 92 96 
GSSG treatment also resulted in the dramatic 
reactivation of a 2-1/2 year old FBPase preparation 
(Table 3). The specific activity of the 854 day old enzyme 
preparation was 2.2 /moles/min/mg. But after the GSSG 
In all cases the pH was 7.5 as described in Materials and 
Methods, except in the determination of the relative 
activity at pH 9.2. For SH group determination, the FBPase 
samples were incubated in 60 mM Tris-HCl (pH 7.5) buffer 
containing 50 MM DTNB for 30 min and the change in 
absorbance at 412 nm was determined. This determination 
was done in the presence and the absence of 8 M urea for 
both the native and the GSSG-Treated FBPases. 
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Table 3. Activation/Reactivation of FBPase by GSSG 
Specific Activity 
Enzyme Age Before GSSG- After GSSG- % increase 
(Days after 
purification) 
Treatment Treatment by GSSG 
10 9.2 121 1215 
854 2.2 88 3900 
The enzyme was prepared according to the procedure given in 
the Materials and Methods section (Han et al., 1982). The 
older enzyme was prepared over two years earlier than the 
newer preparation. A solution of each FBPase sample 
containing 0.2 mg/ml (1.4 /xM) in 0.1M Tris-HCl buffer (pH 
7.5) was incubated at 25°C with 0.2 mM GSSG in the presence 
of 0.2 mM AMP and 0.5 mM MnCl2 (Han et al.,1986). After 12 
h of incubation, aliquots of the control and GSSG-treated 
samples were assayed for activity. The concentration of 
protein in the purified FBPase sample was determined by its 
extinction coefficient at 280 nm and the molecular mass was 
taken to be 144 kDa (Han et al., 1982). The specific 
activities were determined and compared. 
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preparation was 2.2 /xmoles/min/mg. But after the GSSG 
treatment, the old enzyme's specific activity dramatically 
increased to 88 jumoles/min/mg. 
The GSSG-treated FBPase remained stable for more than 4 
hours in an FBPase free crude liver extract. 
Modification of FBPase with Butanedione 
This study reports some of the functional consequences 
of modifying fructose-1,6-bisphosphatase with 2,3 
butanedione, an arginine-specific reagent. Figure 4 shows 
the rapid partial inactivation of FBPase due to treatment 
with 20 mM butanedione for 2 h. The enzyme activity 
decreased 35% after 1.5 h, then levelled off for an 
additional 2 h (not shown). The partial inactivation was 
largely prevented if treatment with butanedione was carried 
out in the presence of 0.5 mM Fru-1,6-P2 or Fru-2,6-P2, the 
latter being more effective (Fig. 5). If 150 mM KC1 is 
included in the assay mixture, the enzyme activity is 
activated 120% above that of the control in the absence of 
KC1. This activation was completely abolished with the 
butanedione treatment. The enzyme activity in the presence 
of 150 mM KC1, decreased from 220% to 65% in 2 h of 
treatment with butanedione (Fig. 4). During the same 2 h 
time period the butanedione treated FBPase became completely 
desensitized to AMP inhibition. The desensitization to AMP 
was 90% complete after 2 h of incubation with butanedione. 
The rate of desensitization to AMP was markedly reduced if 
treatment of the enzyme 
Fig. 4 Effect of Butanedione Treatment on the Activity of 
FBPase Assayed in the Presence and Absence of K+. 
Purified FBPase (0.1 mg/ml) was incubated at 25°C 
with and without 20 mM butanedione in 50 mM borate 
buffer (pH 8.0). Aliquots (10 /xl) were taken at 
the indicated times and assayed in the presence 
and absence of 150 mM KC1 under the conditions as 
described in the Materials and Methods with 5 mM 
MgCl2 as the essential metal cofactor. The 
activities of the untreated control assayed in the 
absence or presence of KC1 remained essentially 
unchanged throughout the experimental period. The 
relative activity of 100% is equivalent to the 
specific activity (/xmole/minute/milligram) of 12.8 
when assayed in the absence of K+. 
Control, Assayed with K+ = Open boxes; BD- 
treated, Assayed with K+ = closed circles; 
Control, Assayed without K+ = Open circles; BD- 
















Fig, 4. Effect of Butanedlone Treatment on the Activity 
of FBPase Assayed in the Presence and Absence of K*. 
Fig. 5 Effect of F-l,6-P2 and F-2,6-P2 on the Butanedione 
Inactivation and Desensitization to AMP Inhibition 
of FBPase. FBPase (0.1 mg/ml), purified as 
described in the Materials and Methods, was 
incubated in 60 mM sodium borate buffer (pH 8.2) 
in the presence and absence of 15 mM butanedione 
and in the presence and absence of 0.5 mM F-l,6-P2 
or F-2,6-P2- At the times indicated, 10 jul 
aliquots were removed and assayed under the 
standard assay conditions as described in the 
Materials and Methods. The activities of the 
enzyme incubated under identical conditions but 
without butanedione ,0.5 mM F-l,6-P2 or F-2,6-P2, 
served as controls and these activities remained 
essentially constant through-out the experimental 
period. The relative activity of 100 is 
equivalent to the specific activity of 12.3 
/xmoles/minute /milligram under the standard assay 

















Fig. 5. Effect of F-I.6-P and F-2.6-P on the Butonedione 
Inactivation of FBPase and on butonedione desensitizetioa 
to BMP Inhibition. 
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was carried out in the presence of Fru-2,6-P2. Fru-1,6-P2 
appears to have little effect on the butanedione-induced 
desensitization of FBPase to AMP inhibition. 
Modification of FBPase with Diethvlpvrocarbonate 
This study reports some of the consequences of 
modifying fructose-1,6-bisphosphatase with diethylpyrocar- 
bonate (DEP), a histidine-specific reagent. Since none of 
the lysine-specific or arginine-specific reagents resulted 
in the complete inactivation of FBPase, attempts were made 
to modify the enzyme with diethylpyrocarbonate and to study 
the functional consequences. 
Figure 6 shows a dramatic loss in FBPase activity due 
to treatment with DEP. More than 98% of the enzyme's 
activity was abolished in 30 min of incubation in the 
presence of 10 mM DEP. This dramatic loss in enzyme 
activity corresponded with an increase in absorbance at 242 
nm, the absorption maximum of carboxyethylated histidine. 
Figure 6 also shows the protection of FBPase from 
inactivation by DEP, with the substrate, fructose-1,6- 
bisphosphate and the potent inhibitor, fructose-2,6- 
bisphosphate. When 500 juM F-l,6-P2 was included in the 
incubation mixture the enzyme was completely protected 
against inactivation by DEP. Similarly when 500 juM F-2,6-P2 
was included in the incubation mixture, the enzyme retained 
88% of its activity in the presence of DEP for at least 30 
min. 
Fig. 6 The Effect of Substrate, AMP and F-2,6-P2 on the 
Inactivation of FBPase by Diethylpyrocarbonate. 
FBPase was purified as described in the Materials 
and Methods. Solutions containing 0.1 mg/ml 
FBPase, 0.2 M sodium acetate (pH 6.5) and 10 mM 
diethylpyrocarbonate were incubated in the 
presence of substrate (500 mM), AMP (500 and 1000 
mM) or F-2,6-P2 (500 mM) for at least 1 hour at 
25°C. At the indicated times 10 /xl aliquots were 
removed and assayed under the standard assay 
conditions as described in the Materials and 
Methods. Relative activity of 100 was equivalent 
to the specific activity of 9.2 jumoles/minute/ 
milligram for the control, which was native FBPase 
incubated in the absence of substrate, AMP, F-2,6- 
P2 and diethylpyrocarbonate. 
Untreated Control = Open Circles; DEP alone = 
Closed Circles; DEP + AMP = Closed Squares; DEP + 



















Fig. 6. The Effect of Substrate, AMP and F-2,6-P2 on the 
Inactivation of FBPase hy Oiethylpyrocarbonote. 
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When AMP at 500 or 1000 (not shown) /iM concentration 
was included in the incubation, no significant level of 
protection of FBPase was observed (Figure 6). 
Radioactivelv Labelled FBPase 
This study was carried out to develop labelled FBPase 
that could be used to monitor enzyme concentration during 
enzyme immobilization studies, enzyme subunit hybridization 
studies and other studies requiring a labelled FBPase. 
Table 4 shows the relevant properties of an FBPase 
sample that was labelled with [3H]-acetic anhydride. The 
enzyme has specific activities of 8.3 units/mg (enzyme 
activity) and 5.4 x 106 dpm/mg (radioactivity). 
Also shown in Table 4 are the relevant properties of an 
FBPase sample that was labelled with [14C]-iodoacetamide. 
The resulting enzyme sample has specific activities of 45.3 
units/mg (enzyme activity) and 5.75 x 105 dpm/mg 
(radioactivity). 
Immobilization of FBPase 
When FBPase was incubated with cystamine-Sepharose 
under the conditions described in MATERIALS AND METHODS, 
approximately 25% of the enzyme was immobilized within 3 h. 
Incubation beyond 3 h did not result in significant further 
coupling. The immobilized enzyme could be released from the 
resin by incubation with 5 mM DTT for 2 h, suggesting the 
formation of disulfide bonds between cysteamine-Sepharose 
and the specific reactive SH groups of FBPase. The amount 
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Table 4. Labelling of FBPase with [14C]-iodoacetamide or 
[3H]-acetic anhydride 
Enzyme Specific Activity 
dpm/mg units/mg 
Native 0 9.2 
Treated with [3H]- 5.4 x 106 8.3 
Acetic anhydride 
Treated with [14C]- 5.75 x 105 45.3 
iodoacetamide 
[14C]-Labelled FBPase was prepared by dissolving 1.4 mg of 
purified FBPase in 1 ml of 50 mM Tris-HCl buffer (pH 7.8) 
containing 2.5 mM iodoacetamide (10 juCi/jumole, 16% hot), 
0.25 mM AMP, and 0.5 mM MnCl2- This reaction mixture was 
allowed to incubate for 8 h at 25°C and aliquots were taken 
at regular intervals to monitor the progress of the 
reaction. The reaction mixture was dialyzed extensively 
with 8 different 1000 volumes of 50 mM Tris-HCl buffer (pH 
7.8) [3H]-Labelled FBPase was prepared by incubating 1.4 mg 
of FBPase in 1 ml of 50 mM borate buffer (pH 8.0) containing 
5 nmole of acetic anhydride (50 nCi) for 30 min at 4-5°C. 
The reaction mixture was dialyzed extensively against 8 
different 1000 volumes of 50 mM borate buffer (pH 8.0). 
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Table 4, Continued 
A sample of each dialyzed labelled enzyme mixture was 
counted in a liquid scintillation counter and its enzyme 
activity assayed. The radioactive and enzymic specific 
activities were determined. 
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of the enzyme bound was found to be equivalent to the 
amount of FBPase protein decreased from the initial 
supernatant fraction. 
Reaction of free enzyme (1.5 /iM) with 50 /xM DTNB in 60 
mM Tris-HCl buffer (pH 7.5) for 30 min showed that 4.2 SH 
groups per molecule of enzyme were titratable. The number 
of titratable SH groups decreased to 2.8 for the enzyme 
remaining in the supernatant fraction after incubation with 
cystamine-Sepharose. The total number of SH groups per 
molecule of enzyme titrated in 8 M urea also decreased for 
the enzyme in the supernatant fraction after incubation with 
cystamine-Sepharose (Table 5). These results highly suggest 
that the larger portion of FBPase interacted with the 
external cysteamine moiety of the bound cystamine (Figure 
7) . The immobilized enzyme retained about 80% of the 
activity of the free form. Like free enzyme, the 
immobilized form was also activated by cystamine, although 
to a lesser extent (Table 5). 
The thermal stability of FBPase increased significantly 
after immobilization (Table 6). Although the immobilized 
enzyme is more stable, it still lost about 50% of its 
activity after storage for 20 days in 0.5 M NaCl at 4°C. 
The presence of albumin (5 mg/ml) significantly enhanced the 
stability of the immobilized enzyme (Figure 8). 
Both the free and immobilized enzymes had an optimum pH 
around 7.5, but the pH activity curve of the immobilized 
enzyme became broader (Figure 9). 
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TABLE 5 
Activation of Free and Immobilized FBPase by Cystamine 
and Iodoacetamide 
Enzyme Treatmenta % Increase in 
Activity 
Free Cystamine (5 mM) 378 
Free Iodoacetamide (5 mM) 302 
Immobilized Cystamine (5 mM) 104 
Immobilized Iodoacetamide (5 mM) 78 
aTreatment of FBPase with cystamine or iodoacetamide was 
carried out at 25°C with gentle shaking in 50 mM Tris buffer 
(pH 8.0). After 4 h, the activity was measured as described 








Alternate Cvsteamine Interaction 
(A) Sepharose-NH-CH2-CH2-S-S-CH2-Ctf2-NH2 
+ FBPase_SH = 
Sepharose-NH-CH2-CH2-S-H + FBPase-SS-CH2-CH2-NH2 
Cvsteamine-Sepharose Seoharose-free Cvsteamine FBPase 
(B) Sepharose-NH-CH2-CH2-S-S-CH2-CH2-WH2 + FBPase-SH = 
Sepharose-NH-CH2-CH2-SS-FBPase 
Cvsteamine-Sepharose Immobilized FBPase 
+ HS-CH2-CH2-NH2 
Sepharose-free Cvsteamine 




Thermal Stability of Free and Immobilized FBPasea 
Residual activity (%) 










Free 89 23 0 
Free, activated 
by cystamine 
95 34 0 
Immobilized 100 48 15 
Immobilized, activated 
by cystamine 100 59 24 
aFree or immobilized enzyme (about 0.2 mg/ml) dissolved or 
suspended in 50 mM Tris buffer (pH 7.5) was incubated in a 
water bath maintained at the indicated temperatures. After 
3 h, the samples were immediately cooled in ice and assayed 
for the residual activity according to the method as shown 
in MATERIALS AND METHODS. Activation by cystamine was 
performed under the same conditions as in Table 5. 
Fig. 8. Effect of albumin on the stability of free and 
immobilized FBPase. FBPase (0.2 mg/ml) was 
incubated at 4°C in 0.5 M NaCl in the presence or 
absence of bovine serum albumin (5 mg/ml). At the 
time intervals indicated, aliquots were removed 
and assayed for FBPase activity under the 
















Fig. 8. Effect of Albumin on the Stability of Free and 
Immobilized FBPase 
Fig. 9. Effect of pH on the activity of free and 
immobilized FBPase. The activity was assayed at 
the indicated pH values under the conditions as 
described in MATERIALS AND METHODS except 50 mM 
Tris buffer (pH 7.5) was replaced by 30 mM 
diethanolamine/30 mM triethanolamine at the 





















The data in Table 7 shows the effectiveness and usefulness 
of the immobilized enzyme for hydrolysis of fructose-1,6-P2 
in the presence of fructose-2,6-P2, an important step in 




Inhibition of Free and Immobilized FBPase Activity by 
Fructose-2 ,6-P2 * 
Enzyme 
Assayed with % Inhibition by Fru-2,6-P2 
Mg2+ or Mn2+ 1 M 10 /XM 
Free 5 mM Mg2+ 72 > 95 
0.2 mM Mn2+ 12 81 
Immobilized 5 mM Mg2+ 33 91 
0.2 mM Mn2+ < 5 32 
aThe activity of FBPase (free or immobilized) was assayed 
under the conditions as described in MATERIALS AND METHODS 
except that the concentration of substrate was reduced to 20 
/iM and fructose-2,6-P2 was added as indicated. In addition, 
the activity was also assayed with 5 mM Mg2+. 
CHAPTER V 
DISCUSSION 
Modification of FBPase with Oxidized Glutathione (GSSG) 
Liver FBPase from all known sources is a tetramer 
composed of identical subunits. A common feature of FBPase 
is the presence of one highly reactive SH group per subunit 
of enzyme molecule and this reactive SH group has been 
located at Cysteine-128 (Chatterjee et al., 1984). A 
previous report from this laboratory showed that GSSG could 
undergo thiol/disulfide exchange with this reactive SH 
group, leading to a marked increase (over 13-fold) in 
catalytic activity (Han et al., 1986). This study has shown 
that activation of FBPase by GSSG is accompanied by changes 
in some enzymatic properties (see RESULTS). The most 
interesting altered property is the marked decrease in 
sensitivity to inhibition by Fru-2,6-P2, a very potent 
inhibitor which is generally considered to play an important 
role in the regulation of FBPase (Van Schaftingen, 1980; 
Hue, 1981 and 1982; Claus, 1981; Richards, 1981; Pontremoli 
et al., 1982; Gottschalk et al., 1982; McGrane et al., 1983 
and Meek and Nimmo, 1983). If GSSG is involved with in vivo 
activation of FBPase, reduced sensitivity to inhibition by 
Fru-2,6-P2 would further ensure the enhancement of gluconeo- 
genesis. The basis for the desensitization to Fru-2,6-P2 
inhibition as the result of GSSG modification is not known 
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since, as mentioned in CHAPTER I, the mechanism of Fru-2,6- 
P2 inhibition of FBPase is still not clearly understood. 
Many researchers believe that Fru-2,6-P2 inhibits FBPase by 
competing with the substrate, Fru-1,6-P2, at the catalytic 
site (Pontremoli et al., 1982; Gottschalk et al., 1982; 
McGrane et al., 1983). If that is the case, then 
modification with GSSG may induce a conformational change at 
a critical microenvironment of the catalytic site. As a 
result, Fru-2,6-P2 may no longer compete with the substrate 
at the catalytic site to cause inhibition. Some 
researchers, however, propose that Fru-2,6-P2 can inhibit 
FBPase by interacting at the allosteric site (Meek and 
Nimmo, 1983). In such case, modification with GSSG may 
prevent the proper interaction of Fru-2,6-P2 with FBPase at 
the allosteric site either by directly blocking the site or 
by indirectly changing the conformation of the 
microenvironment at the allosteric site. 
Han et al. (1983) previously reported that Fru-2,6-P2 
could significantly protect FBPase against inactivation by 
trypsin and these researchers suggested that this inhibitor 
induced a rigid conformation, rendering the proteolytic 
digestion more difficult. It was found in the present study 
that the GSSG-activated enzyme was more resistant to trypsin 
inactivation than the native enzyme. However, the GSSG- 
activated enzyme was no longer responsive to the protective 
effect of Fru-2,6-P2 against inactivation by trypsin. This 
strongly suggests that Fru-2,6-P2 either can not bind to the 
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modified enzyme or it cannot properly interact with the 
enzyme to induce a conformational change which is more 
resistant to tryptic digestion. 
An attempt will be made in the near future to prepare 
radioactively labelled Fru-2,6-P2 to compare the binding of 
this inhibitor to the native and GSSG-modified enzymes. It 
is interesting to observe that the GSSG-incubation of an old 
(over 2 years) FBPase sample that had lost over 82% of the 
12 units/mg specific activity, resulted in an enormous 
increase (about 39-fold) in specific activity. This 
indicates that GSSG not only can activate the freshly 
prepared FBPase but also can reactivate the aged enzyme with 
very low activity. It further suggests that an inactivated 
enzyme may be reactivated by the proper technique of 
chemical modification. 
This enzyme is known for inhibition by high 
concentration of substrate (above 10 /uM) . It was found in 
this study that the enzyme became desensitized to high 
substrate inhibition after treatment with GSSG. Meek and 
Nimmo (1983) have suggested that high levels of substrate 
may inhibit FBPase by binding to another allosteric site 
(distinct from the AMP allosteric site) and that F-2,6-P2 
can inhibit the enzyme by binding at this same allosteric 
site. Han et. al., (1978), have previously reported that 
treatment of chicken liver FBPase with acetylsalicylate 
(ASA), desensitizes the enzyme to inhibition by excess 
substrate without significantly altering the enzyme 
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activity. Han and Hunter (unpublished data) have recently 
found that, like treatment with GSSG, treatment of chicken 
liver FBPase with ASA also resulted in desensitization of 
the enzyme to inhibition by Fru-2,6-P2 and that desensitiza¬ 
tion to both Fru-2,6-P2 and high concentration of Fru-1,6-P2 
by either GSSG or ASA could be prevented if treatments were 
carried out in the presence of either Fru-1,6-P2 (1 mM) or 
Fru-2,6-P2 (0.1 mM). These data strongly suggest that 
inhibition by Fru-2,6-P2 and inhibition by high substrate 
concentration may be correlated and may involve the same 
allosteric site. 
The GSSG-treated FBPase appeared to be quite stable in 
crude liver extract. The activity of the GSSG-activated 
enzyme remained essentially unchanged after incubation for 4 
h in a FBPase-free crude liver cytosol extract which was 
prepared by immunoadsorption using immobilized anti-FBPase 
Sepharose. This indicates that the liver cytosol appears 
not to contain an active enyzme to catalyze the reductive 
dissociation of glutathione from activated G-S-S-FBPase. 
One of the common properties of most FBPases is the 
activation of the native enzyme by monovalent cations. In 
this study the native enzyme in the presence of 150 mM KC1 
exhibited a 120% increase in specific activity at high 
substrate concentration (above 0.1 mM). This activation by 
K+ was completely eliminated after GSSG-treatment. These 
results support the hypothesis that K+ activates FBPase 
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through relief of high substrate inhibition (Singh et al., 
1980). 
Modification of FBPase with Butanedione 
Three different laboratories using FBPase from 
different sources have reported conflicting results upon 
modification of their enzyme with the arginine-specific 
reagent, 2,3-butanedione. Riordan et al. (1977) used rabbit 
muscle FBPase and Zhao Fu-Kun et. al., (1982) used the 
enzyme from snake muscle. In both cases, they found the 
complete loss of catalytic activity and desensitization of 
their enzymes to AMP inhibition upon modification with 
butanedione. Marcus (1976) used FBPase from rabbit liver and 
pig kidney and upon modification with butanedione, also 
found desensitization to AMP inhibition but no loss of 
catalytic activity. This researcher, however, found that 
the butanedione-treated enzyme was no longer responsive to 
the activating effect of monovalent cations (K+ or NH4
+). 
This loss of activation by monovalent cations after 
butanedione treatment was not observed by Fu-Kun et. al. 
(1982) working with the enzyme from snake muscle. The 
results of the present study show that treatment of chicken 
liver FBPase with butanedione resulted in partial 
inactivation, desensitization to AMP inhibition and the 
complete abolishment of activation by K+. It should be 
pointed out that all the different groups of researchers 
conducted the modification reaction under similar conditions 
(i. e., in borate buffer). Since complete loss of catalytic 
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activity was observed only with the enzyme from muscle but 
not with the enzyme from liver or kidney, it is suggested 
that an(some) essential arginyl residue(s) is(are) present 
in muscle FBPase but probably not in liver or kidney FBPase. 
FBPase from most sources is well known for its 
allosteric inhibition by AMP. Chemical modification studies 
of FBPase with specific reagents have shown that tyrosyl, 
lysyl, and arginyl residues are most likely all present at 
the AMP site (Pontremoli et. al., 1966 and 1982; Pilkis et. 
al., 1981; Gottschalk et. al., 1982; Marcus, 1975 and 1976; 
Riordan et al., 1977). Pilkis et. al. (1981), first 
reported that F-2,6-P2 could almost completely protect the 
enzyme against desensitization to AMP inhibition by N- 
acetylimidazole. Subsequently, Gottschalk et. al. (1982), 
reported that F-2,6-P2 could partially protect the enzyme 
against desensitization to AMP inhibition by pyridoxal 
phosphate. We report here that F-2,6-P2 can markedly reduce 
the rate of desensitization of the enzyme to AMP inhibition 
by an arginine-specific reagent, butanedione. Therefore, it 
appears that binding of F-2,6-P2 to the enzyme alters the 
microenvironment of the AMP allosteric site, resulting in 
the decreased reactivities of the functional groups of all 
the above-mentioned three essential amino acid residues. 
Modification of FBPase with Diethvlpvrocarbonate 
Throughout all the modifications done in our 
laboratory, we have never observed the complete inactivation 
of chicken liver FBPase with lysyl-specific and arginyl- 
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specific reagents. Since the substrate is a diphosphate 
anion, one would expect some amino acid residue with a 
positively charged side chain, to be present at the 
catalytic site. It was observed in this study that 
treatment of chicken liver FBPase with diethylpyrocarbonate 
(DEP) led to rapid and almost total loss of catalytic 
activity. Since DEP is highly specific for modifying the 
imidazole group of histidyl residues in protein, it is 
considered that the catalytic site of this enzyme contains 
an(some) essential histidine(s) (DeMaine and Benkovic, 
1980). It was also found that the loss in enzyme activity 
following treatment with DEP corresponded with an increase 
in absorbance at 242 nm. This is consistent with the 
formation of carboxyethylated histidine, the expected 
reaction product of DEP and histidine (Miles, 1977). The 
ability of substrate, F-l,6-P2, to protect the enzyme 
against inactivation by DEP further supports that this 
reagent inactivated the enzyme by modifying the histidyl 
residue(s) at the catalytic site. The fact that F-2,6-P2 
can also provide protection against inactivation by DEP 
suggests that this inhibitor can also interact with the 
catalytic site. 
Immobilization of Fructose-1,6-bisphosphatase 
During the past three decades since FBPase was first 
discovered in rabbit liver by Gomori (1943), FBPase from 
various sources has been extensively investigated. However, 
the immobilization of this enzyme has attracted little 
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attention. In 1973, Falb et al. reported the attachment of 
rabbit liver FBPase to aminoethylcellulose via 
glutaraldehyde. The immobilized enzyme retained only about 
1% of the free enzyme's activity. In 1985, Han et al. 
reported the properties of avian liver FBPase immobilized on 
CNBr-activated Sepharose. This immobilized enzyme retained 
about 38% of the free enzyme's activity. 
Liver FBPase from all known sources is a tetramer 
composed of identical subunits. A common feature of FBPase 
is the presence of one highly reactive SH group/subunit of 
enzyme molecule (Marcus, 1976b; Benkovic and DeMaine, 1982; 
and Chatterjee et al., 1984) and this reactive SH group has 
been located at cysteine-128 using labeled iodoacetamide 
(Chatterjee et al., 1984). In contrast to a common 
phenomenon that most enzymes are inactivated by oxidation or 
modification of free SH groups (Gilbert 1982 and 1984), the 
activity of liver FBPase is activated to varying degrees 
with the modification of FBPase's reactive SH group by many 
SH reagents and disulfides such as cystamine, homocystine, 
and oxidized glutathione (see Pontremoli and Horecker, 1970; 
and Han et al., 1986 for review). This suggests that the 
highly reactive SH group of cysteine-128 can potentially be 
used for preparation of highly active FBPase. 
In this study, we employed cystamine-Sepharose for 
immobilization of liver FBPase. The immobilized enzyme 
retained about 80% of the activity of the free form of the 
enzyme. Immobilization was not observed if the enzyme was 
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first modified with iodoacetamide, suggesting that 
immobilization involves the highly reactive cysteine-128 of 
one or more of the enzyme's tetramer subunits. Activation 
of the immobilized enzyme by cystamine (Table 5) apparently 
resulted from modification of the cysteine-128s of other 
subunits not involved in coupling to the resin. The 
disadvantage of this method is that the amount of enzyme 
bound is only about 25%, apparently due to the fact that the 
larger portion of the enzyme applied has formed disulfide 
bonds with the external cysteamine moeity of the bound 
cystamine. 
We have recently reported that oxidized glutathione 
would undergo thiol/disulfide exchange with chicken liver 
FBPase, resulting in over 13-fold activation (Han et al., 
1986). We have attempted to immobilize FBPase on 
glutathione-Sepharose by incubating the enzyme with oxidized 
glutathione-Sepharose, but the rate of thiol/disulfide 
exchange was found to be very slow. After 10 h of 
incubation, less than 10% of the enzyme was coupled, but the 
enzyme immobilized on glutathione-Sepharose is much more 
active than the enzyme immobilized on cysteamine-Sepharose 
(unpublished). 
The most important progress in FBPase research for the 
past decade was the discovery of fructose-2,6-P2, the 
specific and very potent inhibitor of this enzyme (see 
Tejwani, 1983 for review). The synthesis of this inhibitor 
according to the method of Van Schaftingen and Hers (1981) 
75 
shows that treatment of fructose-1,6-P2 with 
dicyclohexylcarbodiimide in aqueous pyridine resulted in the 
formation of fructose-1,2-cyclic 6-P2 which is converted by 
alkaline hydrolysis to a mixture of fructose-2,6-P2 (15%) 
and fructose-1,6-P2 (85%). Since the two fructose 
bisphosphates formed are difficult to separate from each 
other, fructose-1,6-P2 is selectively hydrolyzed to 
fructose-6-P by FBPase and fructose-6-P is then separated 
from fructose-2,6-P2 by anion exchange chromatography. 
Since the immobilized enzyme can be recovered and 
continuously reutilized, it is feasible to use a large 
quantity of enzyme for each experiment. Thus, the 
immobilized enzyme has the advantage over the free form, in 
the selective hydrolysis of fructose-1,6-P2 in the process 
of fructose-2,6-P2 synthesis. In addition, the enzyme 
immobilized on cysteamine-Sepharose was found to be less 
sensitive to inhibition by fructose-2,6-P2 (data not shown). 
CHAPTER VI 
SUMMARY 
This study has confirmed the previous report that 
treatment of chicken liver FBPase with GSSG leads to a 
marked increase (over 13-fold) in specific activity (Han et 
al., 1986). This study has also shown that activation of 
FBPase by GSSG is accompanied by changes in several specific 
enzymatic properties. The most interesting altered property 
is the marked decrease in sensitivity to inhibition by Fru- 
2,6—P2, a very potent inhibitor which is generally 
considered to play an important role in the regulation of 
FBPase (Van Schaftingen, 1980; Hue, 1981 and 1982; Claus, 
1981; Richards, 1981; Pontremoli et al., 1982; Gottschalk et 
al., 1982; McGrane et al., 1983 and Meek and Nimmo, 1983). 
In addition, the GSSG-treated enzyme was rendered more 
sensitive to inhibition by Zn2+ and more resistant to 
inactivation by the proteolytic enzyme trypsin, while at the 
same time the GSSG-treated enzyme did not show a significant 
change in sensitivity to AMP when compared to the native 
enzyme. The treated enzyme showed no ability to be 
activated by monovalent cations and was only slightly 
responsive to the protective effect of fructose-2,6- 
bisphosphate against inactivation by trypsin. GSSG 
treatment also resulted in the dramatic 40-fold increase in 
activity of a 2-1/2 year old FBPase preparation. These 




The results of the present study also show that treat¬ 
ment of chicken liver FBPase with butanedione resulted in 
partial inactivation, desensitization to AMP inhibition and 
the complete abolishment of activation by K+. F-2,6-P2 
markedly reduced the rate of desensitization of the enzyme 
to AMP inhibition by butanedione making it appear that the 
binding of F-2,6-P2 to the enzyme alters the microenviron¬ 
ment of the AMP allosteric site. 
It was observed in this study that treatment of chicken 
liver FBPase with diethylpyrocarbonate (DEP) led to rapid 
and almost total loss of catalytic activity. Since DEP is 
highly specific for modifying the imidazole group of 
histidyl residues in protein, it is considered that the 
catalytic site of this enzyme contains an(some) essential 
histidine(s) (DeMaine and Benkovic, 1980). It was also 
found that the loss in enzyme activity following treatment 
with DEP corresponded with an increase in absorbance at 242 
nm. The ability of substrate, F-l,6-P2, to protect the 
enzyme against inactivation by DEP further supports that 
this reagent inactivated the enzyme by modifying the histi¬ 
dyl residue(s) at the catalytic site. The fact that F-2,6- 
P2 can also provide protection against inactivation by DEP 
suggests that this inhibitor can also interact with the 
catalytic site. 
Liver fructose 1,6-bisphosphatase was bound to 
cysteamine-Sepharose by thiol/disulfide exchange with 
cystamine-Sepharose. The immobilized enzyme retained about 
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80% of the specific activity of the free enzyme. The 
activity of the immobilized enzyme could further be enhanced 
about 100% by incubation with cystamine. The optimum pH 
remained essentially unchanged but the pH activity curve 
became much broader. The bound enzyme can be released from 
cysteamine-Sepharose by dithiothreitol. The immobilized 
enzyme lost about 50% of activity after storage for 3 weeks 
in 0.5 M NaCl at 4°C. Albumin significantly enhanced the 
stability. The immobilized enzyme is more effective than 
the free form in selective hydrolysis of fructose-1,6- 
bisphosphate in the process of fructose-2,6-bisphosphate 
synthesis. 
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